Literature DB >> 19450878

Hypothesis: how do JAK2-inhibitors work in myelofibrosis.

Ruben Mesa1, Robert Peter Gale.   

Abstract

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19450878     DOI： 10.1016/j.leukres.2009.04.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  3 in total

1.  Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Authors:  G Barosi; M-J Zhang; R Peter Gale
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

2.  Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.

Authors:  Joëlle Rubert; Zhiyan Qian; Rita Andraos; Daniel A Guthy; Thomas Radimerski
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

3.  The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.

Authors:  M Cem Arı; Deram Büyüktaş; A Emre Eşkazan; Seniz Ongören Aydın; Eda Tanrıkulu; Zafer Başlar; A Nur Buyru; Burhan Ferhanoğlu; Yıldız Aydın; Nükhet Tüzüner; Teoman Soysal
Journal:  Turk J Haematol       Date:  2012-10-05       Impact factor: 1.831
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.